Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 26, 2004. The report serves as a notification of a significant corporate governance change rather than a financial results announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is exclusively focused on personnel appointments and contains no financial performance data.
Material Changes
The primary material change disclosed is the appointment of Julian Heslop as the new Chief Financial Officer (CFO). He will succeed John Coombe, who is scheduled to retire on March 31, 2005. Heslop will join the Board of Directors upon Coombe's retirement.
Management Commentary and Outlook
- Transition Plan: Chairman Sir Christopher Hogg stated the Board will work closely with both the outgoing and incoming CFOs to ensure a smooth transition.
- Leadership Endorsement: CEO Dr. JP Garnier described Heslop as a "superb executive" with strong financial and leadership abilities, noting the appointment demonstrates the depth of management talent within the company.
- Background: Heslop, age 50, joined Glaxo Wellcome in 1998 and became Senior Vice President, Operations Controller following the 2001 merger. He is a Fellow of the Institute of Chartered Accountants in England and Wales.
Investor Verification Checklist
- Confirm the effective date of Julian Heslop's appointment to the Board (March 31, 2005).
- Verify the retirement timeline for outgoing CFO John Coombe.
- Review subsequent quarterly reports for any impact on financial strategy or reporting during the transition period.
- Note that this filing contains no financial data; refer to Form 20-F or quarterly earnings releases for performance metrics.